Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following Cox-inhibition evaluated by microarray analysis

Cancer Informatics

Volumn 3, Issue , 2007, Pages 125-139

  Axelsson, Hans ^a   Lönnroth, Christina ^a   Andersson, Marianne ^a   Wang, Wenhua ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Cyclooxygenase; Microarray; RNA expression

Indexed keywords

INDOMETACIN; PROSTAGLANDIN SYNTHASE; RNA; COMPLEMENTARY DNA; CYCLOOXYGENASE 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; INFLAMMATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; SARCOMA; TUMOR GROWTH; UPREGULATION; ADULT; ANIMAL CELL; ANIMAL TISSUE; CARCINOGENICITY; CHROMOSOME; DRUG MECHANISM; GENE AMPLIFICATION; IMAGE ANALYSIS; IN VIVO STUDY; MICROSCOPY; RNA EXTRACTION;

EID: 49649091766     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.1177/117693510700300013     Document Type: Article

References (62)

1. Axelsson, H., Bagge, U. and Lundholm, K. et al. 1997. A one-piece plexi-glass access chamber for subcutaneous implantation in the dorsal skin fold of the mouse. Int. J. Microcirc. Clin.Exp., 17:328-9.
2. Axelsson, H., Lönnroth, C. and Wang, W. et al. 2005. Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice. Angiogenesis, 8:339-48.
3. Baron, J.A., Cole, B.F. and Sandler, R.S. et al. 2003. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348:891-9.
4. Cahlin, C., Gelin, J. and Delbro, D. et al. 2000a. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res., 60:1742-9.
5. Cahlin, C., Korner, A. and Axelsson, H. et al. 2000b. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res., 60:5488-93.
6. Della Bella, S., Molteni, M. and Compasso, S. et al. 1997. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids, 56:177-84.
7. Eberhart, C.E., Coffey, R.J. and Radhika, A. et al. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107:1183-8.
8. Evans, J.F. 2003. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer. Am. J. Clin. Oncol., 26:S62-5.
9. Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285:1182-6.
10. Gelin, J., Andersson, C. and Lundholm, K. 1991. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res., 51:880-5.
11. Giovannucci, E., Egan, K.M. and Hunter, D.J. et al. 1995. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 333:609-14.
12. Giovannucci, E., Rimm, E.B. and Stampfer, M.J. et al. 1994. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121:241-6.
13. Gupta, R.A., Tejada, L.V. and Tong, B.J. et al. 2003. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res., 63:906-11.
14. Harris, S.G., Padilla, J. and Koumas, L. et al. 2002. Prostaglandins as modulators of immunity. Trends Immunol., 23:144-50.
15. Hayashi, N., Yamamoto, H. and Hiraoka, N. et al. 2001. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology, 34:638-50.
16. Hernandez, G.L., Volpert, O.V. and Iniguez, M.A. et al. 2001. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J. Exp. Med., 193:607-20.
17. Huang, M., Stolina, M. and Sharma, S. et al. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res., 58: 1208-16.
18. Huang, R.H., Chai, J. and Tarnawski, A.S. 2006. Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J. Gastroenterol., 12:6446-52.
19. Joo, Y.E., Kim, H.S. and Min, S.W. et al. 2002. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int. J. Gastrointest. Cancer, 31:147-54.
20. Joo, Y.E., Rew, J.S. and Seo, Y.H. et al. 2003. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J. Clin. Gastroenterol., 37: 28-33.
21. Juuti, A., Louhimo, J. and Nordling, S. et al. 2006. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J. Clin. Pathol., 59:382-6.
22. Kandil, H.M., Tanner, G. and Smalley, W. et al. 2001. Cyclooxygenase-2 expression in Barrett's esophagus. Dig. Dis. Sci., 46:785-9.
23. Karim, M.M., Hayashi, Y. and Inoue, M. et al. 2000. Cox-2 expression in retinoblastoma. Am. J. Ophthalmol., 129:398-401.
24. Khan, K.N., Masferrer, J.L. and Woerner, B.M. et al. 2001. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J. Gastroenterol., 36:865-9.
25. Kulkarni, S., Rader, J.S. and Zhang, F. et al. 2001. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res., 7:429-34.
26. Lundholm, K., Daneryd, P. and Korner, U. et al. 2004. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int. J. Oncol., 24:505-12.
27. Lundholm, K., Gelin, J. and Hyltander, A. et al. 1994. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res., 54:5602-6.
28. Lönnroth, C., Andersson, M. and Lundholm, K. 2001. Indomethacin and telomerase activity in tumor growth retardation. Int. J. Oncology, 18:929-937.
29. Lönnroth, C., Svaninger, G. and Gelin, J. et al. 1995. Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int. J. Oncol., 7:1405-1413.
30. Marnett, L.J. and DuBois, R.N. 2002. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol., 42:55-80.
31. Masferrer, J.L., Leahy, K.M. and Koki, A.T. et al. 2000. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60:1306-11.
32. McMillan, D.C., Leen, E. and Smith, J. et al. 1995. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur. J. Surg. Oncol., 21:531-4.
33. Oshima, M., Dinchuk, J.E. and Kargman, S.L. et al. 1996. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87:803-9.
34. Peluffo, G.D., Stillitani, I. and Rodriguez, V.A. et al. 2004. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int. J. Cancer, 110:825-30.
35. Peterson, H.I. 1986. Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res., 6:251-3.
36. Poligone, B. and Baldwin, A.S. 2001. Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J. Biol. Chem., 276:38658-64.
37. Rolland, P.H., Martin, P.M. and Jacquemier, J. et al. 1980. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst., 64:1061-70.
38. Salmenkivi, K., Haglund, C. and Ristimaki, A. et al. 2001. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J. Clin. Endocrinol. Metab., 86:5615-9.
39. Sandler, R.S., Halabi, S. and Baron, J.A. et al. 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 348:883-90.
40. Sawaoka, H., Tsuji, S. and Tsujii, M. et al. 1999. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest., 79:1469-77.
41. Shamma, A., Yamamoto, H. and Doki, Y. et al. 2000. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res., 6:1229-38.
42. Sheng, H., Shao, J. and Kirkland, S.C. et al. 1997. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest., 99:2254-9.
43. Sheng, H., Shao, J. and Morrow, J.D. et al. 1998. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res., 58:362-6.
44. Sheng, H., Shao, J. and Washington, M.K. et al. 2001. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem., 276:18075-81.
45. Shreedhar, V., Giese, T. and Sung, V.W. et al. 1998. A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J. Immunol., 160:3783-9.
46. Siironen, P., Ristimaki, A. and Narko, K. et al. 2006. VEGF-C and COX-2 expression in papillary thyroid cancer. Endocr. Relat. Cancer, 13:465-73.
47. Skopinska-Rozewska, E., Piazza, G.A. and Sommer, E. et al. 1998. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN- 1): a potential mechanism for their antineoplastic properties. Int. J. Tissue React., 20:85-9.
48. Smalley, W., Ray, W.A. and Daugherty, J. et al. 1999. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch. Intern. Med., 159:161-6.
49. Smalley, W.E. and DuBois, R.N. 1997. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Pharmacol., 39:1-20.
50. Thun, M.J., Namboodiri, M.M. and Heath, C.W. Jr. 1991. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325:1593-6.
51. Tkacz, V.L., Tohnya, T.M. and Figg, W.D. 2005. Cyclooxygenase-2 and angiogenesis in prostate cancer. Cancer Biol. Ther., 4:813-4.
52. Tsujii, M., Kawano, S. and DuBois, R.N. 1997. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A., 94:3336-40.
53. Tsujii, M., Kawano, S. and Tsuji, S. et al. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells [published erratum appears in Cell 1998 Jul 24;94(2):following 271]. Cell, 93:705-16.
54. Tuna, B., Yorukoglu, K. and Gurel, D. et al. 2004. Significance of COX-2 expression in human renal cell carcinoma. Urology, 64:1116-20.
55. Uefuji, K., Ichikura, T. and Mochizuki, H. 2001. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J. Surg. Oncol., 76:26-30.
56. Vane, J.R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231:232-5.
57. Williams, C.S., Shattuck-Brandt, R.L. and DuBois., R.N. 1999. The role of COX-2 in intestinal cancer. Expert Opin. Investig. Drugs, 8:1-12.
58. Williams, C.S., Tsujii, M. and Reese, J. et al. 2000. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest., 105:1589-94.
59. Wolff, H., Saukkonen, K. and Anttila, S. et al. 1998. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58:4997-5001.
60. Yamauchi, T., Watanabe, M. and Hasegawa, H. et al. 2003. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res., 23:245-9.
61. Yao, M., Kargman, S. and Lam, E.C. et al. 2003. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res., 63:586-92.
62. Yoshimoto, T., Takahashi, Y. and Kinoshita, T. et al. 2002. Growth stimulation and epidermal growth factor receptor induction in cyclooxygenase-overexpressing human colon carcinoma cells. Adv. Exp. Med. Biol., 507:403-7.